scholarly journals The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma

Cancer ◽  
2005 ◽  
Vol 104 (10) ◽  
pp. 2054-2062 ◽  
Author(s):  
Nina Oestreicher ◽  
Scott D. Ramsey ◽  
Jeannine S. McCune ◽  
Hannah M. Linden ◽  
David L. Veenstra
Keyword(s):  
Adjuvant Chemotherapy ◽  
Breast Carcinoma ◽  
Early Stage ◽  
The Cost

scholarly journals Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma

Cancer ◽  
2005 ◽  
Vol 104 (11) ◽  
pp. 2499-2507 ◽  
Author(s):  
Kristine A. Donovan ◽  
Brent J. Small ◽  
Michael A. Andrykowski ◽  
Frederick A. Schmitt ◽  
Pamela Munster ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Breast Carcinoma ◽  
Cognitive Functioning ◽  
Early Stage

Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy

Cancer ◽  
2003 ◽  
Vol 98 (4) ◽  
pp. 679-689 ◽  
Author(s):  
Alice B. Kornblith ◽  
James E. Herndon ◽  
Raymond B. Weiss ◽  
Chunfeng Zhang ◽  
Enid L. Zuckerman ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Breast Carcinoma ◽  
Early Stage

scholarly journals Delivering adjuvant chemotherapy to women with early-stage breast carcinoma

Cancer ◽  
2001 ◽  
Vol 92 (6) ◽  
pp. 1354-1367 ◽  
Author(s):  
Brian K. Link ◽  
G. Thomas Budd ◽  
Shane Scott ◽  
Elliot Dickman ◽  
David Paul ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Breast Carcinoma ◽  
Early Stage

Breast carcinoma in young females below the age of 35 years - histopathological and prognostic significance

1970 ◽  
Vol 2 (3) ◽  
pp. 198-202
Author(s):  
D Ghartimagar ◽  
A Ghosh ◽  
OP Talwar ◽  
R Narasimhan
Keyword(s):  
Breast Carcinoma ◽  
Young Women ◽  
Early Stage ◽  
Prognostic Significance ◽  
Age Group ◽  
Breast Cancers ◽  
Young Females ◽  
Younger Age ◽  
Grade 3 ◽  
Group Grade

Background: Breast cancers rarely occur in young women but are known to have more aggressive behaviors and poorer outcome. We here compare the significance of breast carcinoma in female below the age of 35 to the age over 35 whose specimens were submitted to Manipal teaching hospital, Pokhara. Materials and Methods: All cases of mastectomy with carcinoma from January 2000 to September 2011 were included in the study. Clinical and histopathological datas of all cases were reviewed and collated. Results: A total of 148 mastectomy specimens were received, among which, 23 cases (16%) were below 35 years; whereas 125 cases (84%) were above 35 years of age. In both groups, Stage II was the commonest stage but stage III was much more common in older group (33% versus 9%) and stage I was more common in younger age group (39% versus 27%). Bloom Richardson grading showed that in the older age group, grade 1 is the commonest grade (50%) while in the younger group; grade 3 is the commonest (39%). Patients were followed for a varying period of 6 months to 5 years. Two cases (2% of followed up cases) in older group and 3 cases (15% of followed up cases) in the younger group showed recurrence. Conclusion: Breast carcinoma in the patients younger than 35 years though presented at an early stage has higher grade tumor and poorer outcome. DOI: http://dx.doi.org/10.3126/jpn.v2i3.6021 JPN 2012; 2(3): 198-202

Insights into Transdermal Drug Delivery: Approaches for Redressal of a Burgeoning Issue of Osteoporosis

2020 ◽  
Vol 20 (10) ◽  
pp. 1682-1695
Author(s):  
Foziyah Zakir ◽  
Kanchan Kohli ◽  
Farhan J. Ahmad ◽  
Zeenat Iqbal ◽  
Adil Ahmad
Keyword(s):  
Drug Delivery ◽  
Transdermal Delivery ◽  
Oral Delivery ◽  
Calcium Absorption ◽  
Early Stage ◽  
Osteoporotic Fractures ◽  
The Novel ◽  
Systemic Delivery ◽  
Primary Focus ◽  
The Cost

Osteoporosis is a progressive bone disease that remains unnoticed until a fracture occurs. It is more predominant in the older age population, particularly in females due to reduced estrogen levels and ultimately limited calcium absorption. The cost burden of treating osteoporotic fractures is too high, therefore, primary focus should be treatment at an early stage. Most of the marketed drugs are available as oral delivery dosage forms. The complications, as well as patient non-compliance, limit the use of oral therapy for prolonged drug delivery. Transdermal delivery systems seem to be a promising approach for the delivery of anti-osteoporotic active moieties. One of the confronting barriers is the passage of drugs through the SC layers followed by penetration to deeper dermal layers. The review focuses on how anti-osteoporotic drugs can be molded through different approaches so that they can be exploited for the skin to systemic delivery. Insights into the various challenges in transdermal delivery and how the novel delivery system can be used to overcome these have also been detailed.

scholarly journals Methodology for the Concept Design of Locally Reinforced Composites

2021 ◽  
Vol 11 (16) ◽  
pp. 7246
Author(s):  
Julius Moritz Berges ◽  
Georg Jacobs ◽  
Sebastian Stein ◽  
Jonathan Sprehe
Keyword(s):  
Cost Estimation ◽  
Structural Design ◽  
Early Stage ◽  
Parameter Study ◽  
Great Effort ◽  
Concept Design ◽  
Cost Weight ◽  
Reinforced Plastics ◽  
Fiber Reinforced Plastics ◽  
The Cost

Locally load-optimized fiber-based composites, the so-called tailored textiles (TT), offer the potential to reduce weight and cost compared to conventional fiber-reinforced plastics (FRP). However, the design of TT has a higher complexity compared to FRP. Current approaches, focusing on solving this complexity for multiple objectives (cost, weight, stiffness), require great effort and calculation time, which makes them unsuitable for serial applications. Therefore, in this paper, an approach for the efficient creation of simplified TT concept designs is presented. By combining simplified models for structural design and cost estimation, the most promising concepts, regarding the cost, weight, and stiffness of TT parts, can be identified. By performing a parameter study, the cost, weight, and stiffness optima of a sample part compared to a conventional FRP component can be determined. The cost and weight were reduced by 30% for the same stiffness. Applying this approach at an early stage of product development reduces the initial complexity of the subsequent detailed engineering design, e.g., by applying methods from the state of the art.

scholarly journals Grid Parity Analysis of China’s Centralized Photovoltaic Generation under Multiple Uncertainties

Energies ◽  
2021 ◽  
Vol 14 (7) ◽  
pp. 1814
Author(s):  
Libo Zhang ◽  
Qian Du ◽  
Dequn Zhou
Keyword(s):  
Power Generation ◽  
Early Stage ◽  
Electricity Price ◽  
Grid Parity ◽  
Industry Environment ◽  
External Conditions ◽  
Generation Costs ◽  
Time Price ◽  
The Cost ◽  
Installed Capacity

The cost of centralized photovoltaic (CPV) power generation has been decreasing rapidly in China. However, the achievement of grid parity is full of uncertainties due to changes in policies and the industry environment. In order to explore the time, price, and external conditions in which grid parity can be achieved, we create the improved grey GM (1, 1) model to estimate the installed capacity over the next 10 years, and apply a learning curve to predict the cost of CPV generation. In the analysis of grid parity, we compare the benchmark price of coal power and the price under the market-oriented mechanism with CPV. The results show that China’s CPV industry will enter the early stage of maturity from 2020 onwards; with the help of benchmark investment, the grid parity of CPV may be achieved in 2022 at the earliest and 2025 at the latest. After 2025, the photovoltaic electricity price will be generally lower than the coal electricity price under marketization. By 2030, CPV power generation costs will reach US $0.05/kWh, the accumulative installed capacity will exceed 370 GW, and the uncertainties will lead to a cumulative installed gap of nearly 100 GW.

Systematic review of adjuvant therapy for early stage (epithelial) ovarian cancer

2003 ◽  
Vol 13 (4) ◽  
pp. 395-404 ◽  
Author(s):  
B. Winter-Roach ◽  
L. Hooper ◽  
H. Kitchener
Keyword(s):  
Systematic Review ◽  
Ovarian Cancer ◽  
Adjuvant Chemotherapy ◽  
Adjuvant Therapy ◽  
Early Stage ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Significant Difference ◽  
Well Differentiated ◽  
Platinum Chemotherapy

A systematic review and meta analysis has been undertaken in order to evaluate the effectiveness of adjuvant therapy following surgery for early ovarian cancer. Trials reported since 1990 have been of a higher quality enabling a meta analysis of adjuvant chemotherapy vs adjuvant radiotherapy and a meta analysis of adjuvant chemotherapy vs observation. There was no significant difference between radiotherapy and chemotherapy, though these comprised studies which demonstrated considerable heterogeneity. Chemotherapy did confer significant benefit over observation in terms of both overall and disease free survival. Except for women in whom adequate surgical staging has revealed well differentiated disease confined to one or both ovaries with intact capsule, platinum chemotherapy should be offered to reduce risk of recurrence.

Sign in / Sign up

Export Citation Format

Share Document